Organization & Developments: DNAtriX

Parents

Alcyone announced a collaboration with DNAtrix to investigate potential use of Alcyone’s microcatheter system for delivering DNAtrix’s anti-cancer agents directly to brain tumors.
The company is developing a new generation of oncolytic virus technology designed to destroy cancer cells while leaving healthy cells unharmed.
The mechanism of action of its first candidate, delta24-RGD adenovirus, is designed to be effective against 90-95% of all cancers. The company has initially focused on malignant brain tumors